drugset / Trial / NCT00727194
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.
Timeline
- Start
- 2008-10
- Primary completion
- 2011-03
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eculizumab | Monoclonal antibody | 900 mg | Intravenous |